• Ligand Pharmaceuticals’ Flex Merger Sub is set to merge into newly formed XOMA Royalty Holdings, leaving XOMA Royalty Holdings as a wholly owned subsidiary of Ligand.
• An amendment dated May 16, 2026 added XOMA Royalty Holdings as a party to the merger agreement originally signed on April 27, 2026.
• XOMA Royalty Holdings was formed to complete a holding company reorganization ahead of the merger.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XOMA Royalty Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-228031), on May 18, 2026, and is solely responsible for the information contained therein.